New York, Jan 5, 2026, 21:27 EST — Market closed
- AbbVie shares fell 4% on Monday, underperforming a broader market advance.
- The drugmaker is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
- Traders are watching technical support near long-term averages ahead of late-January earnings season.
AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high.
The move mattered because drug and biotech names were among the day’s laggards as investors rotated into energy and financials after Venezuela headlines lifted oil-linked stocks. The NYSE Arca Pharmaceutical Index fell about 1.4% and the SPDR S&P Biotech ETF slid 1.1%, while the Health Care Select Sector SPDR ETF dipped 0.3%.
AbbVie also put a near-term spotlight on its calendar, saying it will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14. Management will take part in a “fireside chat,” an on-stage interview format, at 10:15 a.m. Central time, with a live webcast on its investor relations site.
In the broader market, financial and energy shares led gains after a U.S. military strike captured Venezuelan President Nicolás Maduro, Reuters reported. “The mood has been favoring financial stocks in recent days,” said Steve Sosnick, chief market analyst at Interactive Brokers.
AbbVie’s drop outpaced declines in several large-cap pharma peers on a day when the S&P 500 rose 0.64%, according to MarketWatch. Johnson & Johnson fell 1.47%, Pfizer slipped 0.04% and Amgen lost 2.11%.
Volume in AbbVie was elevated, with about 8.9 million shares traded versus a 50-day average near 5.5 million, MarketWatch said. Heavy volume can signal investors are repositioning rather than drifting on light trade.
Technically, AbbVie is now roughly 10% below its 52-week high of $244.81, MarketWatch said. The stock is also sitting below its 50-day moving average — a widely watched trend line that smooths daily price swings — near $226.54, with the 200-day moving average around $214.39, MarketBeat data showed.
On fundamentals, Wall Street will soon pivot back to earnings. Zacks said analysts expect AbbVie to deliver quarterly earnings of $3.37 per share on revenue of $16.37 billion, with full-year earnings of $10.64 per share on revenue of $60.93 billion; it also pegged AbbVie’s forward P/E — the price investors pay for a dollar of expected profit — at about 15.9 times.
MarketBeat estimated AbbVie’s next earnings are due around Jan. 30 before the market opens, based on past reporting schedules, though the company has not confirmed a date. Investors will be listening for any tone shift on 2026 demand trends and the pace of growth in newer products as the company works to sustain momentum in the post-Humira era.
The risk is that the sector rotation away from defensives persists if energy stays bid or rates move higher, keeping pressure on big pharma valuations. Any unexpected commentary on pricing, competition or the pipeline during investor events can also widen daily swings in a stock that typically trades with lower volatility than the broader market.
Next up, traders will watch Friday’s U.S. nonfarm payrolls report for clues on rates, and AbbVie’s Jan. 14 fireside chat at the J.P. Morgan Healthcare Conference for signals on priorities heading into earnings season.
